Genetic and non-genetic factors affecting the response to clopidogrel therapy

Bibliography

• Herbert JM, Savi P. P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med 2003;3:113-22
   PubMedGoogle Scholar
• Anderson JL, Adams CD, Antman EM, ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction – executive summary. J Am Coll Cardiol 2007;50:652-726
   Web of Science ®Google Scholar
• Antman EM, Anbe DT, Armstrong PW, ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction – executive summary. Circulation 2004;110:588-636
   PubMed Web of Science ®Google Scholar
• Smith SC, Feldman TE, Hirshfeld JW, ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention – summary article. J Am Coll Cardiol 2006;47:216-35
   PubMed Web of Science ®Google Scholar
• Harker LA, Boissel JP, Pilgrim AJ, Gent M. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf 1999;21:325-35
   PubMed Web of Science ®Google Scholar
• De Miguel A, Ibanez B, Badimon JJ. Clinical implications of clopidogrel resistance. Thromb Haemost 2008;100:196-203
   PubMed Web of Science ®Google Scholar
• Combescure C, Fontana P, Mallouk N, Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2010;8:923-33
   PubMed Web of Science ®Google Scholar
• Taubert D, von Beckerath N, Grimberg G, Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006;80:486-501
   PubMed Web of Science ®Google Scholar
• Kazui M, Nishiya Y, Ishizuka T, Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010;38:92-9
   PubMed Web of Science ®Google Scholar
• Bouman HJ, Schomig E, van Werkum JW, Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011;17:110-16
   PubMed Web of Science ®Google Scholar
• Savi P, Pereillo JM, Uzabiaga MF, Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891-6
   PubMed Web of Science ®Google Scholar
• Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008;99:466-72
   PubMed Web of Science ®Google Scholar
• Fontana P, Dupont A, Gandrille S, Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003;108:989-95
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Etherington A, Tantry US. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. Thromb Res 2007;121:107-15
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Becker RC, Mann KG. Platelet function monitoring in patients with coronary artery disease. JACC 2007;50:1822-34
   Google Scholar
• Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost 2007;5:230-7
   PubMed Web of Science ®Google Scholar
• Linnemann B, Schwonnberg J, Rechner AR, Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y. Ann Hematol 2010;89:597-605
   PubMed Web of Science ®Google Scholar
• Swallow RA, Agarwala RA, Dawkins KD, Curzen NP. Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy? Platelets 2006;17:385-92
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R, Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-33
   PubMed Web of Science ®Google Scholar
• Bonello L, Camoin-Jau L, Armero S, Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009;103:5-10
   PubMed Web of Science ®Google Scholar
• Results of the TRIGGER-PCI trial reported at TCT 2011. Available from: http://medicalxpress.com/news/2011-11-results-trigger-pci-trial-tct.html [Last accessed 26 January 2012]
   Google Scholar
• Price MJ, Berger PB, Teirstein PS, Standard- vs. high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention. JAMA 2011;305:1097-205
   PubMed Web of Science ®Google Scholar
• Bonello L, Armero S, Ait Mokhtar O, Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. J Am Coll Cardiol 2010;56:1630-6
   PubMed Web of Science ®Google Scholar
• Mega J, Hochholzer W, Frelinger AL, Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011;306:2221-8
   PubMed Web of Science ®Google Scholar
• Yin T, Miyata T. Pharmacogenomics of clopidogrel: evidence and perspectives. Thromb Res 2011;128:307-16
   PubMed Web of Science ®Google Scholar
• Wallentin L, James S, Storey RF, Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010;376:1320-8
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-75
   PubMed Web of Science ®Google Scholar
• FDA. Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. 03-12-2010. Available from: www.fda.gov/drugs/drugsafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm [Last accessed 26 January 2012]
   Google Scholar
• Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol 2007;2:93-109
   PubMedGoogle Scholar
• Shuldiner AR, O'Connell JR, Bliden KP, Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849-57
   PubMed Web of Science ®Google Scholar
• Fontana P, James R, Barazer I, Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study. J Thromb Haemost 2011;9:1664-6
   PubMed Web of Science ®Google Scholar
• Barker CM, Murray SS, Teirstein PS, Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. J Am Coll Cardiol Interv 2010;3:1001-7
   Google Scholar
• Bouman HJ, Harmsze AM, van Werkum JW, Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart 2011;97:1239-44
   PubMed Web of Science ®Google Scholar
• Brandt JT, Close SL, Iturria SJ, Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007;5:2429-36
   PubMed Web of Science ®Google Scholar
• Collet JP, Hulot JS, Anzaha G, High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). J Am Coll Cardiol Interv 2011;4:392-402
   Google Scholar
• Collet JP, Hulot JS, Pena A, Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309-17
   PubMed Web of Science ®Google Scholar
• Fontana P, Hulot JS, de Moerloose P, Gaussem P. Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J Thromb Haemost 2007;5:2153-5
   PubMed Web of Science ®Google Scholar
• Frere C, Cuisset T, Morange PE, Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 2008;101:1088-93
   PubMed Web of Science ®Google Scholar
• Geisler T, Schaeffeler E, Dippon J, CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 2008;9:1251-9
   PubMed Web of Science ®Google Scholar
• Giusti B, Gori AM, Marcucci R, Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 2009;103:806-11
   PubMed Web of Science ®Google Scholar
• Giusti B, Gori AM, Marcucci R, Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 2007;17:1057-64
   PubMed Web of Science ®Google Scholar
• Gladding P, Webster M, Zeng I, The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. J Am Coll Cardiol Interv 2008;1:620-7
   Google Scholar
• Harmsze A, van Werkum JW, Bouman HJ, Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenet Genomics 2010;20:18-25
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Fromm MF, Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010;55:2427-34
   PubMed Web of Science ®Google Scholar
• Hulot JS, Bura A, Villard E, Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006;108:2244-7
   PubMed Web of Science ®Google Scholar
• Jinnai T, Horiuchi H, Makiyama T, Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Circ J 2009;73:1498-503
   PubMed Web of Science ®Google Scholar
• Kim IS, Jeong YH, Park Y, Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. J Am Coll Cardiol Interv 2011;4:381-91
   Google Scholar
• Lee JM, Park S, Shin DJ, Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. Am J Cardiol 2009;104:46-51
   PubMed Web of Science ®Google Scholar
• Maeda A, Ando H, Asai T, Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine. Clin Pharmacol Ther 2011;89:229-33
   PubMedGoogle Scholar
• Mega JL, Close SL, Wiviott SD, Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62
   PubMed Web of Science ®Google Scholar
• Oh IY, Park KW, Kang SH, Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart 2012;98:139-44
   PubMed Web of Science ®Google Scholar
• Park KJ, Chung HS, Kim SR, Clinical, pharmacokinetic and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome. Korean J Lab Med 2011;31:91-4
   PubMedGoogle Scholar
• Park KW, Park JJ, Lee SP, Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial. Heart 2011;97:641-7
   PubMedGoogle Scholar
• Pettersen AA, Arnesen H, Opstad TB, Seljeflot I. The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel. Thromb J 2011;9:4
   PubMedGoogle Scholar
• Umemura K, Furuta T, Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost 2008;6:1439-41
   PubMed Web of Science ®Google Scholar
• Mega JL, Simon T, Collet JP, Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010;304:1821-30
   PubMed Web of Science ®Google Scholar
• Bauer T, Bouman HJ, van Werkum JW, Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011;343:d4588
   PubMed Web of Science ®Google Scholar
• Holmes MV, Perel P, Shah T, CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011;306:2704-14
   PubMed Web of Science ®Google Scholar
• Frere C, Cuisset T, Gaborit B, The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. J Thromb Haemost 2009;7:1409-11
   PubMed Web of Science ®Google Scholar
• Tiroch KA, Sibbing D, Koch W, Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J 2010;160:506-12
   PubMed Web of Science ®Google Scholar
• Sibbing D, Koch W, Gebhard D, Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010;121:512-18
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006;2:1895-900
   Google Scholar
• Suh JW, Koo BK, Zhang SY, Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006;174:1715-22
   PubMed Web of Science ®Google Scholar
• Smith SMG, Judge HM, Peters G, Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets 2006;17:250-8
   PubMed Web of Science ®Google Scholar
• Lee SJ, Jung IS, Jung EJ, Identification of P2Y12 single-nucleotide polymorphisms and their influences on the variation in ADP-induced platelet aggregation. Thromb Res 2011;127:220-7
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res 2005;116:491-7
   PubMed Web of Science ®Google Scholar
• von Beckerath N, von Beckerath O, Koch W, P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis 2005;16:199-204
   PubMed Web of Science ®Google Scholar
• Motovska Z, Widimsky P, Kvasnicka J, High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial. Blood Coagul Fibrinolysis 2009;20:257-62
   PubMedGoogle Scholar
• Staritz P, Kurz K, Stoll M, Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene. Int J Cardiol 2009;133:341-5
   PubMed Web of Science ®Google Scholar
• Sibbing D, Koch W, Massberg S, No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 2011;32:1605-13
   PubMed Web of Science ®Google Scholar
• Ohmori T, Yano Y, Sakata A, Lack of association between serum paraoxonase-1 activity and residual platelet aggregation during dual anti-platelet therapy. Thromb Res 2011; published online 23 November 2011; doi:10.1016/j.thromres.2011.10.033.
   Google Scholar
• Hulot JS, Collet JP, Cayla G, CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv 2011;4:422-8
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010;376:1312-19
   PubMed Web of Science ®Google Scholar
• Spiewak M, Małek ŁA, Kostrzewa G, Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes. Kardiol Pol 2009;67:827-34
   PubMed Web of Science ®Google Scholar
• Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol 2011;57:1251-63
   PubMed Web of Science ®Google Scholar
• Sibbing D, Morath T, Stegherr J, Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009;101:714-19
   PubMed Web of Science ®Google Scholar
• Gilard M, Arnaud B, Cornily JC, Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-60
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Ueno M, Capodanno D, Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study. Circ Cardiovasc Interv 2010;3:436-41
   PubMed Web of Science ®Google Scholar
• Small DS, Farid NA, Payne CD, Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008;48:475-84
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Gomes T, Ko DT, A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-18
   PubMed Web of Science ®Google Scholar
• Ho PM, Maddox TM, Wang L, Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. J Am Med Assoc 2009;301:937-44
   PubMed Web of Science ®Google Scholar
• Lau WC, Waskell LA, Watkins PB, Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003;107:32-7
   PubMed Web of Science ®Google Scholar
• Gorchakova O, von Beckerath N, Gawaz M, Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 2004;25:1898-902
   PubMed Web of Science ®Google Scholar
• Mitsios JV, Papathanasiou AI, Rodis FI, Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004;109:1335-8
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008;52:1557-63
   PubMed Web of Science ®Google Scholar
• Gremmel T, Steiner S, Seidinger D, Calcium-channel blockers decrease clopidogrel- mediated platelet inhibition. Heart 2010;96:186-9
   PubMed Web of Science ®Google Scholar
• Farid NA, Payne CD, Small DS, Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735-41
   PubMed Web of Science ®Google Scholar
• Harmsze AM, Van Werkum JW, Moral F, Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. Platelets 2011;22:98-102
   PubMed Web of Science ®Google Scholar
• Feher G, Koltai K, Alkonyi B, Clopidogrel resistance: body mass index and concomitant medications. Int J Cardiol 2007;120:188-92
   PubMed Web of Science ®Google Scholar
• Sibbing D, von Beckerath N, Morath T, Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur Heart J 2010;31:1205-11
   PubMed Web of Science ®Google Scholar
• Judge HM, Patil SB, Buckland RJ, Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel. J Thromb Haemost 2010;8:1820-7
   PubMed Web of Science ®Google Scholar
• Gajos G, Rostoff P, Undas A, Piwowarska W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention. The OMEGA-PCI (OMEGA-3 Fatty Acids After PCI to Modify Responsiveness to Dual Antiplatelet Therapy) Study. J Am Coll Cardiol 2010;55:1671-8
   PubMed Web of Science ®Google Scholar
• Lev EI, Arikan ME, Vaduganathan M, Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease. J Am Coll Cardiol 2011;57:694e1-7
   Google Scholar
• Lau WC, Welch TD, Shields T, The Effect of St. John's wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP 3A4 metabolic activity. J Cardiovasc Pharmacol 2011;57:86-93
   PubMed Web of Science ®Google Scholar
• Farhan S, Hochtl T, Kautzky-Willer A, Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus. Wien Med Wochenschr 2010;160:30-8
   PubMedGoogle Scholar
• Bhatt DL, Marso SP, Hirsch AT, Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90:625-8
   PubMed Web of Science ®Google Scholar
• Harding SA, Sarma J, Din JN, Clopidogrel reduces platelet–leucocyte aggregation, monocyte activation and RANTES secretion in type 2 diabetes mellitus. Heart 2006;92:1335-7
   PubMed Web of Science ®Google Scholar
• Ang L, Palakodeti V, Khalid A, Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol 2008;52:1052-9
   PubMedGoogle Scholar
• Angiolillo D, Fernandez-Ortiz A, Bernardo E, Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005;54:2430-5
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bernardo E, Ramirez C, Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 2006;48:298-304
   PubMed Web of Science ®Google Scholar
• Cuisset T, Frere C, Quilici J, Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. Thromb Res 2009;123:597-603
   PubMed Web of Science ®Google Scholar
• El Ghannudi S, Ohlmann P, Jesel L, Impaired inhibition of P2Y12 by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention. Atherosclerosis 2011;217:465-72
   PubMedGoogle Scholar
• Erlinge D, Varenhorst C, Braun OO, Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008;52:1968-77
   PubMed Web of Science ®Google Scholar
• Geisler T, Anders N, Paterok M, Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007;30:372-4
   PubMed Web of Science ®Google Scholar
• Geisler T, Mueller K, Aichele S, Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions. Clin Res Cardiol 2010;99:743-52
   PubMedGoogle Scholar
• James S, Angiolillo DJ, Cornel JH, Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010;31:3006-16
   PubMed Web of Science ®Google Scholar
• Mangiacapra F, Patti G, Peace A, Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. Am J Cardiol 2010;106:619-23
   PubMed Web of Science ®Google Scholar
• Serebruany V, Pokov I, Kuliczkowski W, Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost 2008;100:76-82
   PubMed Web of Science ®Google Scholar
• van Werkum JW, Topcu Y, Postma S, Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel. Thromb Haemost 2008;99:637-9
   PubMed Web of Science ®Google Scholar
• Gaborit B, Frere C, Cuisset T, Enhanced post-clopidogrel platelet reactivity in diabetic patients is independently related to plasma fibrinogen level but not to glycemic control. Thromb Haemost 2009;7:1939-41
   Google Scholar
• Geisler T, Graß D, Bigalke B, The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score. J Thromb Haemost 2008;6:54-61
   PubMed Web of Science ®Google Scholar
• Fontana P, Berdague P, Castelli C, Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. J Thromb Haemost 2010;8:2614-23
   PubMed Web of Science ®Google Scholar
• Park SH, Kim W, Park CS, A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol 2009;104:1292-5
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bernardo E, Capodanno D, Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 2010;55:1139-46
   PubMed Web of Science ®Google Scholar
• Keltai M, Tonelli M, Mann JF, Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil 2007;14:312-18
   PubMed Web of Science ®Google Scholar
• Best PJ, Steinhubl SR, Berger PB, The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2008;155:687-93
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Steinhubl SR, Bhatt DL, Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] trial). Am J Cardiol 2009;103:1359-63
   PubMed Web of Science ®Google Scholar
• James S, Budaj A, Aylward P, Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function results from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation 2010;122:1056-67
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Panagiotou A, Xanthapoulou I, Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. J Thromb Haemost 2011;9:2379-85
   PubMed Web of Science ®Google Scholar
• Basili S, Pacini G, Guagnano MT, Insulin resistance as a determinant of platelet activation in obese woman. J Am Coll Cardiol 2006;48:2531-8
   PubMed Web of Science ®Google Scholar
• Dellas C, Schafer K, Rohm IK, Leptin signaling and leptin-mediated activation of human platelets: importance of JAK2 and the phospholipases Cgamma2 and A2. Thromb Haemost 2007;98:1063-71
   PubMed Web of Science ®Google Scholar
• Alessi MC. Juhan-Vague I: metabolic syndrome, haemostasis and thrombosis. Thromb Haemost 2008;99:995-1000
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 2004;16:169-74
   PubMedGoogle Scholar
• Sibbing D, von Beckerath O, Schomig A, Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am J Cardiol 2007;100:203-5
   PubMed Web of Science ®Google Scholar
• Kelly RV, Hsu A, Topol E, Steinhubl S. The influence of body mass index on outcomes and the benefit of antiplatelet therapy following percutaneous coronary intervention. J Invasive Cardiol 2006;18:115-19
   PubMedGoogle Scholar
• Soffer D, Moussa I, Harjai KJ, Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv 2003;59:21-5
   PubMed Web of Science ®Google Scholar
• Motovska Z, Widimsky P, Petr R, Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking ‘‘paradox''. J Cardiovasc Pharmacol 2009;53:368-72
   PubMed Web of Science ®Google Scholar
• Schror K. Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel. Vasc Med 1998;3:247-51
   PubMedGoogle Scholar
• Bernlochner I, Steinhubl S, Braun S, Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Thromb Haemost 2010;104:1193-200
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26
   PubMed Web of Science ®Google Scholar
• Park DW, Lee SW, Yun SC, A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation. J Am Coll Cardiol 2011;58:2630-9
   PubMed Web of Science ®Google Scholar
• Muhlestein JB. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thromb Haemost 2010;103:71-82
   PubMed Web of Science ®Google Scholar
• Gori AM, Cesari F, Marcucci F, The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. Atherosclerosis 2009;202:255-62
   PubMed Web of Science ®Google Scholar
• Guthikonda S, Alviar CL, Vaduganathan M, Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008;52:743-9
   PubMed Web of Science ®Google Scholar
• Berger JS, Bhatt DL, Steinhubl SR, Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation 2009;120:2337-44
   PubMed Web of Science ®Google Scholar
• Bliden KP, DiChiara J, Lawal L, The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 2008;52:531-3
   PubMed Web of Science ®Google Scholar
• Desai NR, Mega JL, Jiang S, Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 2009;53:1273-8
   PubMed Web of Science ®Google Scholar
• Sibbald M, Yan AT, Huang W, Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: insights from the global registry of acute coronary events. Am Heart J 2010;160:855-61
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Capranzano P, Ferreiro JL, Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. Thromb Haemost 2011;106:253-62
   PubMedGoogle Scholar
• Mega JL, Close SL, Wiviott SD, Cytochrome P450 genetic polymorphisms and the response to prasugrel. Circulation 2009;119:2553-60
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Dimitropoulos G, Davlouros P, Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv 2011;4:403-10
   PubMed Web of Science ®Google Scholar
• Bliden KP, Tantry US, Storey RF, The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity. Am Heart J 2011;34:160-5
   Google Scholar
• Angiolillo DJ, Guzman LA. Clinical overview of promising nonthienopyridine antiplatelet agents. Am Heart J 2008;156:S23-8
   PubMed Web of Science ®Google Scholar